Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational
| العنوان: | Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational |
|---|---|
| المؤلفون: | Martin Sénécal, Michael A Marentette, Ruth McPherson, Claude Gagné, George Fodor, Marc-André Lavoie, Jacques Genest, Rolf J. Sebaldt |
| المصدر: | Current Medical Research and Opinion. 25:47-55 |
| بيانات النشر: | Informa Healthcare, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, Canada, medicine.medical_specialty, Statin, Cross-sectional study, medicine.drug_class, Low density lipoprotein cholesterol, Coronary Artery Disease, law.invention, Coronary artery disease, chemistry.chemical_compound, Randomized controlled trial, law, Internal medicine, medicine, Humans, cardiovascular diseases, Aged, Dyslipidemias, business.industry, Cholesterol, Cholesterol, LDL, General Medicine, Middle Aged, medicine.disease, Cross-Sectional Studies, chemistry, Physical therapy, Female, lipids (amino acids, peptides, and proteins), Observational study, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Dyslipidemia |
| الوصف: | Several randomized controlled trials indicate that a low density lipoprotein cholesterol (LDL-C) target2.0 mmol/L is appropriate for individuals at high risk of coronary artery disease (CAD). Recently released Canadian lipid management guidelines (2006) have incorporated this evidence into their recommendations. A cross-sectional study of patients treated with statins for at least 8 weeks (CALIPSO) was used as a basis to project the ability of statin monotherapy in getting high CAD-risk patients to an LDL-C level2.0 mmol/L.The analysis was restricted to CALIPSO patients on statin monotherapy who were at high CAD-risk (including patients with established CAD). Assuming all patients could have their statin titrated up to the maximum dose, the proportion of patients that would reach an LDL-C level of2.0 mmol/L was projected. To do this, the additional LDL-C reduction patients would achieve with maximal titration of their statin was estimated based on a meta-analysis of clinical trials evaluating LDL-C responses to various statin regimens, and applied to patients' current LDL-C level.A total of 1795 high CAD-risk patients treated with statin monotherapy were included in the analysis, of whom 69.8% had an LDL-Cor =2.0 mmol/L. Depending on the statin that was used, it was projected that between 28.2% and 62.7% of high CAD-risk patients would not attain an LDL-C of2.0 mmol/L following statin titration to maximum dose.Although the accuracy of our projections may be limited by the application of clinical trials data to an external sample of patients, our results suggest that for 38% of patients at high CAD-risk, titration of statin monotherapy will not be sufficient to achieve an LDL-C target of2.0 mmol/L. For these patients, additional treatment approaches may be needed to further reduce the risk of coronary events. |
| تدمد: | 1473-4877 0300-7995 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603b27db6299478aed516a3e473e3282 https://doi.org/10.1185/03007990802575734 |
| رقم الأكسشن: | edsair.doi.dedup.....603b27db6299478aed516a3e473e3282 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 14734877 03007995 |
|---|